<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256330</url>
  </required_header>
  <id_info>
    <org_study_id>2019-04179</org_study_id>
    <nct_id>NCT04256330</nct_id>
  </id_info>
  <brief_title>Cardiometabolic Health and Inflammatory Resolution</brief_title>
  <acronym>REX</acronym>
  <official_title>Cardiometabolic Health and Inflammatory Resolution (Kardiometabol hälsa Och Inflammatorisk Resolution)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine how inflammatory resolution impacts cardiometabolic
      health and disease in subjects that are either lean (18.5-24.9 kg/m2), overweight (25.0-29.9
      kg/m2) or obese (&gt;30.0 kg/m2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory status</measure>
    <time_frame>2025</time_frame>
    <description>The inflammatory status will be studied in all 6 groups.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Volunteers</condition>
  <arm_group>
    <arm_group_label>Lean and metabolically healthy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean and metabolically unhealthy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight and metabolically healthy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight and metabolically unhealthy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese and metabolically healthy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese and metabolically unhealthy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects are recruited either via open adds of after having indicated in previous study
        registers that they are interested in participating as volunteers in future studies.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed signed consent has been obtained from the volunteer.

          -  The volunteer has a BMI greater than 18.5 kg/m2

        Exclusion Criteria:

          -  The study staff contacting a potential participant perceives that the individual has
             difficulty understanding the information.

          -  An MD determines that the individual is on too many medications to participate

          -  The individual takes a medication that is approved by the MD, but he/she is not
             willing or not able to wait with any potential morning medication until after their
             fasted blood-draw.

          -  The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)

          -  The individual states that they have increased bleeding tendency or are using
             anti-coagulant (blood thinning) medication.

          -  The individual has some form of chronic inflammation.

          -  The individual regularly uses medication that affects inflammatory resolution (e.g.,
             low-dose aspirin).

          -  The individual uses immunosuppressive drugs (eg, methotrexate).

          -  The individual regularly consumes fish oils (omega 3).

          -  The individual has significant gastrointestinal problems.

          -  The individual smokes or uses chewing tobacco.

          -  The individual has been drinking alcohol two days before the study visit.

          -  The individual has tattoos or body piercings on the forearms and / or the stomach that
             can affect the examination.

          -  The individual does not follow instructions given in the research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Emma Börgeson, PhD</last_name>
    <phone>+46313423833</phone>
    <email>emma.borgeson@wlab.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per-Anders Jansson, MD, PhD</last_name>
    <phone>+46313420000</phone>
    <email>Per-Anders.Jansson@wlab.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gothenburg university</name>
      <address>
        <city>Gothenburg</city>
        <state>Vastra Gotaland</state>
        <zip>41669</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Börgeson, PhD</last_name>
      <phone>+46313420000</phone>
      <email>emma.borgeson@wlab.gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Per-Anders Jansson, PhD, MD</last_name>
      <phone>+46313420000</phone>
      <email>Per-Anders.Jansson@wlab.gu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

